DESC:The following specification describes the invention.

INTRODUCTION
Aspects of the present application relate to amorphous Filgotinib maleate, its solid dispersion and pharmaceutical compositions thereof. Aspects of the present application further relate to processes for the preparation of amorphous form and amorphous solid dispersion of Filgotinib maleate.
The drug compound having the adopted name “Filgotinib” has chemical name: Cyclopropanecarboxylic acid {5-[4-(1,1-dioxo- thiomorpholin-4-ylmethyl)- phenyl]-[1,2,4]triazolo[1,5- a]pyridin-2-yl}-amide as below.

Filgotinib is a selective Jak-1 inhibitor developed by Galapagos NV and its maleate salt is under clinical studies as a oral treatment for various conditions such as Rheumatoid arthritis, Crohn’s disease; Ulcerative colitis and Psoriatic Arthritis.
US 8088764 B2 first discloses Filgotinib and its usefulness for the treatment of conditions such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases and its pharmaceutical compositions. Further, it discloses preparative methods for the preparation of compounds disclosed therein including Filgotinib by reacting N-(5-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide with 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)thiomorpholine 1,1-dioxide. The product was isolated by extracting into ethyl acetate followed by purification by flash chromatography. However, US 8088764 B2 does not disclose any salt form of Filgotinib.
US 2018007043 A1 describes a process for the preparation of maleate salt of Filgotinib by suspending a mixture of Filgotinib in 5% aqueous acetone and maleic acid in tetrahydrofuran overnight followed by filtration of the solids, which is characterized by XRPD as a crystalline Filgotinib maleate. Further, WO/2018/169875 A also discloses a similar procedure for the preparation of crystalline Filgotinib maleate, designated as Form I characterized by an XRPD pattern comprising peaks at 8.2, 11.9, 16.4, and 18.9 °2? ± 0.2 °2? as determined on a diffractometer using Cu-Ka radiation.
Hence, there remains a need for alternate solid forms of Filgotinib maleate and preparative processes thereof, exhibiting desired bioavailability and stability. Hence, it is desirable to provide a viable solid form of Filgotinib maleate.

SUMMARY
In an aspect, the present application provides amorphous form of Filgotinib maleate.

In another aspect, the present application provides a process for the preparation of amorphous form of Filgotinib maleate, comprising the steps of:
a) providing a solution of Filgotinib maleate in an inert solvent;
b) removing the solvent from the solution obtained in step a); and
c) isolating amorphous form of Filgotinib maleate.

In another aspect, the present application provides amorphous solid dispersion of Filgotinib maleate together with atleast one pharmaceutically acceptable excipient.

In another aspect, the present application provides a process for the preparation of amorphous solid dispersion of Filgotinib maleate together with atleast one pharmaceutically acceptable excipient, comprising the steps of:
a) providing a solution of Filgotinib maleate and atleast one pharmaceutically acceptable excipient in an inert solvent;
b) removing the solvent from the solution obtained in step a), and
c) isolating amorphous solid dispersion of Filgotinib maleate.

In another aspect, the present application provides a pharmaceutical composition comprising amorphous form of Filgotinib maleate and atleast one pharmaceutically acceptable excipient.

In another aspect, the present application provides a pharmaceutical composition comprising amorphous solid dispersion of Filgotinib maleate together with atleast one pharmaceutically acceptable excipient and atleast one additional pharmaceutically acceptable excipient.

BRIEF DESCRIPTION OF THE DRAWING
Figure 1 is an illustrative X-ray powder diffraction pattern of amorphous form of Filgotinib maleate prepared by the method of Example No 1.
Figure 2 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Filgotinib maleate prepared by the method of Example No 2.
Figure 3 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Filgotinib maleate prepared by the method of Example No 3.
Figure 4 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Filgotinib maleate prepared by the method of Example No 4.
Figure 5 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Filgotinib maleate prepared by the method of Example No 5.
Figure 6 is an illustrative X-ray powder diffraction pattern of amorphous form of Filgotinib maleate prepared by the method of Example No 6.
Figure 7 is an illustrative X-ray powder diffraction pattern of amorphous form of Filgotinib maleate and Syloid prepared by the method of Example No 7.
Figure 8 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Filgotinib maleate prepared by the method of Example No 8.
Figure 9 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Filgotinib maleate prepared by the method of Example No 9.
Figure 10 is an illustrative X-ray powder diffraction pattern of amorphous solid dispersion of Filgotinib maleate prepared by the method of Example No 10.

DETAILED DESCRIPTION
In an aspect, the present application provides an amorphous form of Filgotinib maleate.
In another aspect, the present application provides a stable amorphous form of Filgotinib maleate. The present application provides a stable amorphous form of Filgotinib maleate suitable for powder handling and downstream processes. Amorphous form of Filgotinib maleate of the present application was surprisingly found to be highly stable under mechanical stress such as grinding and blending. Amorphous Filgotinib maleate was found to be stable under both thermal conditions, such as temperature of about 40 ? and high relative humidity conditions such as more than 60% RH and / or about 75% RH.
In embodiments, the present application provides amorphous form of Filgotinib maleate with less than 5% of crystallinity, preferably with less than 1% crystallinity and more preferably with less than 0.5% crystallinity as per X-ray diffraction analysis.
In embodiments, the present application provides an amorphous form of Filgotinib maleate characterized by a powder X-ray diffraction (PXRD) pattern, substantially as illustrated by Figures 1 or 6.
Amorphous form of Filgotinib maleate exhibits a higher bioavailability than its crystalline counterparts, viable enough to prefer amorphous form for pharmaceutical dosage form development. The solubility of crystalline form is lower than its amorphous form, particularly aqueous solubility, which results in the difference in their in-vivo bioavailability. Therefore, it is desirable to have an amorphous form of Filgotinib maleate to meet the needs of drug product development.

In another aspect, the present application provides a process for the preparation of amorphous form of Filgotinib maleate, comprising the steps of:
a) providing a solution of Filgotinib maleate in an inert solvent;
b) removing the solvent from the solution obtained in step a); and
c) isolating amorphous form of Filgotinib maleate.
In embodiments, inert solvent of step a) may be selected from the group consisting of C1-C6 alcohols, C3-C6 ketones, C2-C6 aliphatic or cyclic ethers, C5-C8 aliphatic or aromatic hydrocarbons, C3-C6 esters, C2-C6 nitriles, halogenated hydrocarbons, water and mixtures thereof.
In preferred embodiment, the inert solvent may be selected from the group consisting of methanol, ethanol, 2-propanol, 1-butanol, 2-butanol, 1-pentanol, 2-pentanol, 3-pentanol, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, water and mixtures thereof.
In embodiments, providing a solution at step a) may be carried out by dissolving Filgotinib maleate in an inert solvent or by directly taking the reaction mixture containing Filgotinib maleate in an inert solvent. In embodiments, a solution of Filgotinib maleate can be prepared at any suitable temperatures of about 0°C to reflux temperature of the solvent used.
In embodiments, a solution of Filgotinib maleate may be filtered to make it clear and free of unwanted particles. In embodiments, the obtained solution may be optionally treated with an adsorbent material, such as carbon and/or hydrose, to remove colored components, etc., before filtration.
In embodiments, removal of solvent at step b) may be carried out by methods known in the art or any procedure disclosed in the present application.
In embodiments, removal of solvent may be carried out through solvent evaporation under atmospheric pressure or reduced pressure / vacuum using suitable equipment such as Büchi® rotavapor, spray drying, freeze drying, agitated thin film drying (ATFD), rotary vacuum paddle dryer (RVPD) and the like.
In embodiments, the solvent may be removed at suitable temperatures of less than about 100°C, less than about 80°C, less than about 40°C, less than about 20°C, less than about 0°C, less than about -20°C, less than about -40°C, less than about -60°C, less than about -80°C, or any other suitable temperatures.
In embodiments, the isolation of an amorphous form of Filgotinib maleate at step c) involves recovering the solid obtained in step b). The solid obtained from step b) may be recovered using techniques such as by scraping, or by shaking the container, or triturating with a solvent to make slurry followed by filtration, or other techniques specific to the equipment used. In an embodiment, the amorphous form of Filgotinib maleate obtained from step b) may be optionally dried before or after isolating it at step c).
Amorphous form of Filgotinib maleate obtained at step c) may be optionally combined with atleast one pharmaceutically acceptable excipient at step d).
In an embodiment, amorphous form of Filgotinib maleate may be combined with excipient using a technique known in art or by the procedures disclosed in the present application.
In embodiments, amorphous form of Filgotinib maleate may be combined with excipient either by physical blending of both the solid components or by suspending both the components in a suitable solvent and conditions, such that both the components remain unaffected. Blending may be carried out using techniques known in art such as rotatory cone dryer, fluidized bed dryer or the like optionally under reduced pressure / vacuum or inert atmosphere such nitrogen at suitable temperature and sufficient time to obtain uniform composition of amorphous form of Filgotinib maleate and atleast one pharmaceutically acceptable excipient.
In embodiments, pharmaceutically acceptable excipient may include, but not limited to an inorganic oxide such as SiO2, TiO2, ZnO2, ZnO, Al2O3 and zeolite; a water insoluble polymer is selected from the group consisting of cross-linked polyvinyl pyrrolidinone, cross-linked cellulose acetate phthalate, cross-linked hydroxypropyl methyl cellulose acetate succinate, microcrystalline cellulose, polyethylene/polyvinyl alcohol copolymer, polyethylene/polyvinyl pyrrolidinone copolymer, cross-linked carboxymethyl cellulose, sodium starch glycolate, cross-linked styrene divinyl benzene or any other suitable excipient.
In preferred embodiment, pharmaceutically acceptable excipient may be selected from the group consisting of silicon dioxide, e.g. colloidal or fumed silicon dioxide or porous silica or Syloid; copolymers, such as polyethylene/polyvinyl alcohol copolymer, polyethylene/polyvinyl pyrrolidinone copolymer; and cellulose, preferably microcrystalline cellulose.
Amorphous form of Filgotinib maleate isolated at step c) or d) may be dried in suitable drying equipment such as vacuum oven, rotatory cone dryer, air oven, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying may be carried out at atmospheric pressure or under reduced pressures at temperatures of less than about 100°C, less than about 60°C, less than about 40°C, or any other suitable temperatures. The drying may be carried out for any time period required for obtaining a desired quality, such as from about 15 minutes to 10 hours or longer.
In another aspect, the present application provides pharmaceutical composition comprising amorphous form of Filgotinib maleate and atleast one pharmaceutically acceptable excipient.

In another aspect, the present application provides amorphous solid dispersion of Filgotinib maleate together with atleast one pharmaceutically acceptable excipient.
In embodiments, pharmaceutically acceptable excipient of this aspect may be selected from the group consisting of polyvinyl pyrrolidone, povidone K-30, povidone K-60, Povidone K-90, polyvinylpyrrolidone vinylacetate, co-povidone NF, polyvinylacetal diethylaminoacetate (AEA®), polyvinyl acetate phthalate, polysorbate 80, polyoxyethylene–polyoxypropylene copolymers (Poloxamer® 188), polyoxyethylene (40) stearate, polyethyene glycol monomethyl ether, polyethyene glycol, poloxamer 188, pluronic F-68, methylcellulose, methacrylic acid copolymer (Eudragit or Eudragit-RLPO), hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate (HPMC-AS), hydroxypropylmethyl cellulose, hydroxypropyl cellulose SSL(HPC-SSL), hydroxypropyl cellulose SL(HPC-SL), hydroxypropyl cellulose L (HPC-L), hydroxyethyl cellulose, Soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL-PVAc-PEG)), gelucire 44/14, ethyl cellulose, D-alpha-tocopheryl polyethylene glycol 1000 succinate, cellulose acetate phthalate, carboxymethylethylcelluloseand the like; cyclodextrins, gelatins, hypromellose phthalates, sugars, polyhydric alcohols, and the like; water soluble sugar excipients, preferably having low hygroscopicity, which include, but are not limited to, mannitol, lactose, fructose, sorbitol, xylitol, maltodextrin, dextrates, dextrins, lactitol and the like; polyethylene oxides, polyoxyethylene derivatives, polyvinyl alcohols, propylene glycol derivatives and the like; organic amines such as alkyl amines (primary, secondary, and tertiary), aromatic amines, alicyclic amines, cyclic amines, aralkyl amines, hydroxylamine or its derivatives, hydrazine or its derivatives, and guanidine or its derivatives, or any other excipient at any aspect of present application. The use of mixtures of more than one of the pharmaceutical excipients to provide desired release profiles or for the enhancement of stability is within the scope of this invention. Also, all viscosity grades, molecular weights, commercially available products, their copolymers, and mixtures are all within the scope of this invention without limitation. Solid dispersions of the present application also include the solid dispersions obtained by combining Filgotinib maleate with a suitable non-polymeric excipient by employing techniques known in the art or procedures described or exemplified in any aspect of the instant application.
In an embodiment, the present application provides an amorphous solid dispersion of Filgotinib maleate together with Povidone.
In an embodiment, the present application provides an amorphous solid dispersion of Filgotinib maleate together with Copovidone.
In an embodiment, the present application provides an amorphous solid dispersion of Filgotinib maleate together with HPC.
In an embodiment, the present application provides an amorphous solid dispersion of Filgotinib maleate together with HPMC.
In an embodiment, the present application provides an amorphous solid dispersion of Filgotinib maleate together with HPMC AS.
In an embodiment, the present application provides an amorphous solid dispersion of Filgotinib maleate together with Eudragit.
In an embodiment, the present application provides an amorphous solid dispersion of Filgotinib maleate together with HPMC AS and Eudragit.
In an embodiment, the present application provides amorphous solid dispersion of Filgotinib maleate together with atleast one pharmaceutically acceptable excipient characterized by a powder X-ray diffraction (PXRD) pattern, substantially as illustrated by Figures 2, 3, 4, 5, 8, 9 and 10.

In another aspect, the present application provides a process for the preparation of amorphous solid dispersion of Filgotinib maleate together with atleast one pharmaceutically acceptable excipient, comprising the steps of:
a) providing a solution of Filgotinib maleate and atleast one pharmaceutically acceptable excipient in an inert solvent;
b) removing the solvent from the solution obtained in step a), and
c) isolating amorphous solid dispersion of Filgotinib maleate.
In embodiments, inert solvent of step a) may be selected from the group consisting of C1-C6 alcohols, C3-C6 ketones, C2-C6 aliphatic or cyclic ethers, C5-C8 aliphatic or aromatic hydrocarbons, C3-C6 esters, C2-C6 nitriles, halogenated hydrocarbons, water and mixtures thereof.
In preferred embodiments, inert solvent may be selected from the group consisting of methanol, ethanol, 2-propanol, 1-butanol, 2-butanol, 1-pentanol, 2-pentanol, 3-pentanol, dichloromethane, tetrahydrofuran, 1-4-dioxane, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, water and mixtures thereof.
In embodiments, atleast one pharmaceutically acceptable excipient of this aspect may be selected from the group of excipients of the previous aspect.
In embodiments, providing a solution at step a) may be carried out by dissolving Filgotinib maleate and atleast one pharmaceutically acceptable excipient simultaneously or separately in same or different solvents.
In embodiments, a solution of Filgotinib maleate and the excipient may be prepared at any suitable temperatures of about 0°C to reflux temperature of the solvent used.
In embodiments, a solution of Filgotinib maleate and the excipient may be filtered to make it clear and free of unwanted particles. In embodiments, the obtained solution may be optionally treated with an adsorbent material, such as carbon and/or hydrose, to remove colored components, etc., before filtration.
In embodiments, removal of solvent at step b) may be carried out by methods known in the art or any procedure disclosed in the present application. In preferred embodiments, removal of solvent may be carried out through solvent evaporation under atmospheric pressure or reduced pressure / vacuum using suitable equipment such as Büchi® rotavapor, spray drying, freeze drying, agitated thin film drying and the like.
In embodiments, the solvent may be removed at temperatures of less than about 100°C, less than about 80°C, less than about 40°C, less than about 20°C, less than about 0°C, less than about -20°C, less than about -40°C, less than about -60°C, less than about -80°C or any other suitable temperatures.
In embodiments, the isolation of an amorphous solid dispersion of Filgotinib maleate with excipient at step c) involves recovering the solid obtained in step b). The solid obtained from step b) may be recovered using techniques such as by scraping, or by shaking the container, or triturating with a solvent to make slurry followed by filtration, or other techniques specific to the equipment used.
In embodiments, the amorphous solid dispersion of Filgotinib maleate and excipient obtained from step b) may be optionally dried before or after isolating at step c).
Amorphous solid dispersion of Filgotinib maleate obtained at step c) may be optionally combined with atleast one additional pharmaceutically acceptable excipient.
In an embodiment, amorphous solid dispersion of Filgotinib maleate may be combined with additional excipient using a technique known in art or according to the previous aspects of the present application.
Amorphous solid dispersion of Filgotinib maleate isolated at step c) or d) may be dried in a suitable drying equipment such as tray dryer, vacuum oven, rotatory cone dryer, air oven, fluidized bed dryer, spin flash dryer, flash dryer, or the like. The drying may be carried out at atmospheric pressure or under reduced pressures at temperatures of less than about 100°C, less than about 60°C, less than about 40°C, or any other suitable temperatures. The drying may be carried out for any time period required for obtaining a desired quality, such as from about 15 minutes to 10 hours or longer.

Amorphous Filgotinib maleate and the solid dispersions of the present application were found to be stable under both thermal conditions, such as temperature of about 40 ? and high relative humidity conditions such as more than 60% RH and / or about 75% RH. The stable amorphous Filgotinib maleate and its solid dispersions are suitable for powder handling and downstream processes and highly stable under mechanical stress such as grinding and blending.

In an aspect, the present application provides pharmaceutical composition comprising amorphous solid dispersion of Filgotinib maleate together with atleast one pharmaceutically acceptable excipient and atleast one additional pharmaceutically acceptable excipient.
In an aspect, the present application provides pharmaceutical compositions comprising amorphous Filgotinib maleate and atleast one pharmaceutically acceptable excipient, in particular in the form of solid dispersions and adsorbates, and a process for preparing the same. In embodiments, the pharmaceutically acceptable excipient is selected from the excipients at any aspect of present application.
In embodiments, the present application provides adsorbates, wherein Filgotinib maleate is associated with a suitable substrate. Suitable substrate may be a particulate and/or porous substrate, wherein this substrate has an outer and/or inner surface onto which the API may be adsorbed. This means that if the substrate has pores, these pores are filled by the Filgotinib maleate and the substrate remains unaffected, it does not, at least not essentially, change during and / or after the adsorption. In embodiments, the suitable substrate is selected from the excipients at any aspect of present application.
Amorphous form of Filgotinib maleate or its solid dispersion may be obtained alternatively either by employing a melt-extrusion technique or by combining a solution of Filgotinib maleate as obtained any of the aspects of present application with a suitable anti-solvent. In embodiments, amorphous product may be obtained by employing suitable melt-extrusion conditions or any of the procedures known in the art for obtaining amorphous product by melt-extrusion technique. In embodiments, solution of Filgotinib maleate may be combined with the anti-solvent at suitable temperature and for sufficient time to obtain amorphous product. Suitable anti-solvent is a solvent, wherein Filgotinib maleate has low solubility.
In another aspect, the present application provides amorphous Filgotinib maleate, its solid dispersion with atleast one pharmaceutically acceptable excipient or a pharmaceutical composition thereof; comprising Filgotinib maleate having a chemical purity of atleast 99% by HPLC or atleast 99.5% by HPLC or atleast 99.9% by HPLC.
Certain specific aspects and embodiments of the present application will be explained in greater detail with reference to the following examples, which are provided only for purposes of illustration and should not be construed as limiting the scope of the application in any manner. Variations of the described procedures, as will be apparent to those skilled in the art, are intended to be within the scope of the present application.
Definitions
The term "about" when used in the present application preceding a number and
referring to it, is meant to designate any value which lies within the range of ±10%, preferably within a range of ±5%, more preferably within a range of ±2%, still more preferably within a range of ±1 % of its value. For example "about 10" should be construed as meaning within the range of 9 to 11 , preferably within the range of 9.5 to 10.5, more preferably within the range of 9.8 to 10.2, and still more preferably within the range of 9.9 to 10.1.
The term “inert solvent” when used in the present application is a solvent that does not react with the reactants or reagents under conditions that cause the chemical reaction indicated to take place.
The terms “amorphous form of Filgotinib maleate" and “amorphous Filgotinib maleate” indicate that the Filgotinib maleate is present in substantially amorphous state in the composition (e.g. solid dispersion, adsorbate or pharmaceutical composition). "Substantially" amorphous denotes that 90 %, preferably 95 % or 99 %, more preferably all of the Filgotinib maleate being present in the solid dispersion, on the adsorbate or in the pharmaceutical composition is amorphous. In other words, an "amorphous" Filgotinib maleate composition denotes a Filgotinib maleate-containing composition, which does not contain substantial amounts, preferably does not contain noticeable amounts, of crystalline portions of Filgotinib maleate e.g. measurable upon X-ray powder diffraction analysis.
The term "solid dispersion" when used in the present application, denotes a state where most of the Filgotinib maleate, preferably 90%, 95% or all of the Filgotinib maleate of the solid dispersion, is homogeneously molecularly dispersed in a solid polymer matrix. Preferably solid dispersion, relates to a molecular dispersion where the API (active pharmaceutical ingredient) and polymer molecules are uniformly but irregularly dispersed in a non-ordered way. In other words, in a solid dispersion, the two components (polymer and API) form a homogeneous one-phase system, where the particle size of the API in the solid dispersion is reduced to its molecular size. In a preferred embodiment, in the solid dispersion according to the present invention no chemical bonds can be detected between the API and the polymer. In order to arrive at such a solid dispersion, preferably solid solution, it is required to have a substantial amount of API dissolved in a suitable solvent at least at one time point during preparation of said solid dispersion.
The term "adsorbate" when used in the present application, specifies that the Filgotinib maleate is, preferably evenly, and preferably homogeneously, distributed on the inner and/or outer surface of the particulate substrate.
An “alcohol” is an organic compound containing a carbon bound to a hydroxyl group. “C1-C6 alcohols” include, but are not limited to, methanol, ethanol, 2-nitroethanol,2-fluoroethanol, 2,2,2-trifluoroethanol, hexafluoroisopropyl alcohol, ethylene glycol, 1-propanol, 2-propanol (isopropyl alcohol), 2-methoxyethanol, 1-butanol, 2-butanol, i-butyl alcohol, t-butyl alcohol, 2-ethoxyethanol, diethylene glycol, 1-, 2-, or 3-pentanol, neo-pentyl alcohol, t-pentyl alcohol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, phenol, glycerol, or the like.
An “aliphatic hydrocarbon” is a liquid hydrocarbon compound, which may be linear, branched, or cyclic and may be saturated or have as many as two double bonds. A liquid hydrocarbon compound that contains a six-carbon group having three double bonds in a ring is called“aromatic.” Examples of “C5-C8aliphatic or aromatic hydrocarbons” include, but are not limited to, n-pentane, isopentane, neopentane, n-hexane, isohexane, 3-methylpentane, 2,3-dimethylbutane, neohexane, n-heptane, isoheptane, 3-methylhexane, neoheptane, 2,3-dimethylpentane, 2,4-dimethylpentane, 3,3-dimethylpentane, 3-ethylpentane, 2,2,3-trimethylbutane, n-octane, isooctane, 3-methylheptane, neooctane, cyclohexane, methylcyclohexane, cycloheptane, benzene, toluene, ethylbenzene, m-xylene, o-xylene, p-xylene, trimethylbenzene, chlorobenzene, fluorobenzene, trifluorotoluene, anisole, or any mixtures thereof.
An “ester” is an organic compound containing a carboxyl group -(C=O)-O- bonded to two other carbon atoms. “C3-C6esters” include, but are not limited to, ethyl acetate, n-propyl acetate, n-butyl acetate, iso propyl acetate, isobutyl acetate, t-butyl acetate, ethyl formate, methyl acetate, methyl propanoate, ethyl propanoate, methyl butanoate, ethyl butanoate, or the like.
An “ether” is an organic compound containing an oxygen atom –O- bonded to two other carbon atoms. “C2-C6 ethers” include, but are not limited to, diethyl ether, diisopropyl ether, methyl t-butyl ether, glyme, diglyme, tetrahydrofuran, 2-methyltetrahydrofuran, 1,4-dioxane, dibutyl ether, dimethylfuran, 2-methoxyethanol, 2-ethoxyethanol, anisole, or the like.
A “halogenated hydrocarbon” is an organic compound containing a carbon bound to a halogen. Halogenated hydrocarbons include, but are not limited to, dichloromethane, 1,2-dichloroethane, trichloroethylene, perchloroethylene, 1,1,1-trichloroethane, 1,1,2-trichloroethane, chloroform, carbon tetrachloride, or the like.
A “ketone” is an organic compound containing a carbonyl group -(C=O)- bonded to two other carbon atoms. “C3-C6 ketones” include, but are not limited to, acetone, ethyl methyl ketone, diethyl ketone, methyl isobutyl ketone, ketones, or the like.
A “nitrile” is an organic compound containing a cyano -(C=N) bonded to another carbon atom. “C2-C6Nitriles” include, but are not limited to, acetonitrile, propionitrile, butanenitrile, or the like.

EXAMPLES
Example-1: Preparation of Amorphous form of Filgotinib maleate
Filgotinib maleate (0.5 g) was dissolved in 1,4-dioxane (100 mL) at 75°C and the clear solution was taken into a Buchi® flask and the solvent was evaporated completely using rotavapor under vacuum at 85°C to obtain the title compound. XRPD: Amorphous.

Example-2: Preparation of Amorphous solid dispersion of Filgotinib maleate with HPC
Filgotinib maleate (0.25 g) and HPC (0.25 g) were dissolved in mixture of methanol (10 mL) and dichloromethane (40 mL) at 45°C and the solution was filtered to make it particle free. The clear solution was taken into a Buchi flask and the solvent was evaporated completely using rotavapor under vacuum at 45°C to obtain title compound. XRPD: Amorphous.

Example-3: Preparation of Amorphous solid dispersion of Filgotinib maleate and Copovidone.
Filgotinib maleate (0.25 g) and Copovidone (0.25 g) were dissolved in mixture of methanol (10 mL) and dichloromethane (40 mL) at 45°C and the solution was filtered to make it particle free. The clear solution was taken into a Buchi flask and the solvent was evaporated completely using rotavapor under vacuum at 45°C to obtain title compound. XRPD: Amorphous.

Example-4: Preparation of Amorphous solid dispersion of Filgotinib maleate and Povidone K-30.
Filgotinib maleate (0.25 g) and Povidone K-30 (0.25 g) were dissolved in mixture of methanol (10 mL) and dichloromethane (40 mL) at 45°C and the solution was filtered to make it particle free. The clear solution was taken into a Buchi flask and the solvent was evaporated completely using rotavapor under vacuum at 45°C to obtain title compound. XRPD: Amorphous.

Example-5: Preparation of Amorphous solid dispersion of Filgotinib maleate and HPMC.
Filgotinib maleate (0.25 g) and HPMC (0.25 g) were dissolved in mixture of methanol (10 mL) and dichloromethane (40 mL) at 45°C and the solution was filtered to make it particle free. The clear solution was taken into a Buchi flask and the solvent was evaporated completely using rotavapor under vacuum at 45°C to obtain title compound. XRPD: Amorphous

Example-6: Preparation of Amorphous form of Filgotinib maleate
Filgotinib maleate (1.5 g) was dissolved in a mixture of methanol (40 mL) and dichloromethane (40 mL) at 65°C and the clear solution was taken into a Buchi® flask and the solvent was evaporated completely using rotavapor under vacuum at 65°C to obtain 1.3 g of the title compound. XRPD: Amorphous.

Example-7: Preparation of Amorphous Filgotinib maleate and syloid.
Amorphous Filgotinib maleate (0.5 g) obtained in example-6 was blended with Syloid (100 mg) in rotavapor for 15 minutes obtain the title compound. XRPD: Amorphous.

Example-8: Preparation of Amorphous solid dispersion of Filgotinib maleate and HPMC AS.
Filgotinib maleate (1.5 g) and HPMC AS LG (1.5 g) were dissolved in a mixture of methanol (100 mL) and dichloromethane (100 mL) at 45°C and the clear solution was taken into a Buchi® flask and the solvent was evaporated completely using rotavapor under vacuum at 65°C to obtain 2.4 g of the title compound. XRPD: Amorphous.

Example-9: Preparation of Amorphous solid dispersion of Filgotinib maleate and Eudragit E100.
Filgotinib maleate (1.5 g) and Eudragit E100 (1.5 g) were dissolved in a mixture of methanol (40 mL) and dichloromethane (40 mL) at 25°C and the clear solution was taken into a Buchi® flask and the solvent was evaporated completely using rotavapor under vacuum at 65°C to obtain 2.7 g of the title compound. XRPD: Amorphous.

Example-10: Preparation of Amorphous solid dispersion of Filgotinib maleate and with HPMC AS and Eudragit E100.
Filgotinib maleate (1.0 g), HPMC AS LG (0.5 g) and Eudragit E100 (0.5 g) were dissolved in a mixture of methanol (50 mL) and dichloromethane (50 mL) at 65°C and the clear solution was taken into a Buchi® flask and the solvent was evaporated completely using rotavapor under vacuum at 65°C to obtain 1.65 g of the title compound. XRPD: Amorphous.

Example-11: Stability of amorphous form and its solid dispersions of Filgotinib maleate.
Following thermal studies at various conditions such as 25 ? & 30 % RH for 6 days; 40 °C / 75 % RH for 24 Hours in humidity chamber and at 40 °C in for 24 hours air tray drier, were carried out to assess the stability of said solid forms of Filgotinib maleate (FM) in open condition.

Ex. no. Solid form 25 ? / 30 % RH for 6 days 40 °C for 24 hours 40 °C / 75% RH for 24 Hours
6 Amorphous FM Amorphous Amorphous NA*
7 Amorphous FM + Syloid NA* Amorphous NA*
8 Solid dispersion with HPMC AS Amorphous Amorphous Amorphous
9 Solid dispersion with Eudragit Amorphous Amorphous NA*
10 Solid dispersion with Eudragit + HPMC AS NA* Amorphous NA*
NA: No details available
,CLAIMS:1. Amorphous form of Filgotinib maleate.
2. A process for the preparation of amorphous form of Filgotinib maleate, comprising the steps of:
a. providing a solution of Filgotinib maleate in an inert solvent;
b. removing the solvent from the solution obtained in step a); and
c. isolating amorphous form of Filgotinib maleate.
3. An amorphous solid dispersion of Filgotinib maleate together with atleast one pharmaceutically acceptable excipient.
4. A process for the preparation of amorphous solid dispersion of claim 6, comprising the steps of:
a. providing a solution of Filgotinib maleate and atleast one pharmaceutically acceptable excipient in an inert solvent;
b. removing the solvent from the solution obtained in step a), and
c. isolating amorphous solid dispersion of Filgotinib maleate.
5. The solid dispersion of claim 3 or 4, wherein the excipient is selected from the group consisting of Hydroxypropyl methyl cellulose (HPMC), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate (HPMC-AS), hydroxypropyl cellulose (HPC), hydroxypropyl cellulose SSL(HPC-SSL), hydroxypropyl cellulose SL(HPC-SL), hydroxypropyl cellulose L (HPC-L), polyvinyl pyrrolidone, povidone K-30, povidone K-60, Povidone K-90, polyvinylpyrrolidone vinylacetate, co-povidone NF and methacrylic acid copolymer (Eudragit).
6. The process of claim 2 or 4, wherein the inert solvent of step a) is selected from the group consisting of methanol, ethanol, propanol, butanol, pentanol, dichloromethane, tetrahydrofuran, 1,4-dioxane, acetone, methyl ethyl ketone, methyl isobutyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, water and mixtures thereof.
7. The process of claim 2 or 4, wherein the solvent is removed under reduced pressure.
8. The process of claim 2 or 4, wherein the solvent is removed at temperature of less than 100 ?.
9. The process of clam 2 or 4, further comprising the step of combining amorphous form or amorphous solid dispersion of Filgotinib maleate, with atleast one pharmaceutically acceptable excipient.
10. The process of claim 9, wherein pharmaceutically acceptable excipient is syloid.